Clinical Trial to Evaluate the Efficacy and Safety of Cellgram-LC Administration in Patients With Alcoholic Cirrhosis

Phase 3RecruitingNCT04689152

Pharmicell Co., Ltd.200 enrolled

Overview

The goal of this clinical trial is to evaluate the efficacy and safety of Cellgram-LC in patients with alcoholic cirrhosis. The main questions it aims to answer are: * Is Cellgram-LC superior to best supportive care (BSC) in patients with alcoholic cirrhosis? * What medical problems do participants have after receiving Cellgram-LC compared with BSC? Participants will: * Receive a single dose of Cellgram-LC at Week 0 or receive best supportive care according to their assigned study group. * Attend clinic visits for scheduled assessments at Week 4 and Months 3, 6, 9, 12, 18, and 24. * Complete scheduled telephone follow-up at Months 2, 4, 5, 7, 8, 10, 11, 15, 21, 27, 30, 33, and 36. * Be followed for transplant-free survival and other study outcomes.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

200

Conditions

Alcoholic Cirrhosis

Interventions

Eligibility

Sex: ALLMin age: 20 YearsMax age: 71 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. At the time of screening, 19 or 70 years 2. Patients diagnosed with alcoholic cirrhosis by combining alcohol history, imaging and pathological examination results, and clinical symptoms at screening, and belonging to Child-Pugh grade B or C (Child-Pugh score of 7 or more) 3. Those whose survival period is more than 1 year when judged by the tester 4. Those who can perform hepatic artery catheterization by inserting a catheter into the hepatic artery at the judgment of the examiner 5. In the case of women of childbearing potential, a person who was confirmed negative in the pregnancy test at screening and agreed to use contraception\* by the method permitted for this clinical trial during the clinical trial 6. Those who can conduct clinical trials according to the clinical trial protocol 7. A person who has consented in writing to voluntarily participate in this clinical trial Exclusion Criteria: 1. Those with a history of solid cancer including Hepatocellular Carcinoma (HCC) (within 5 years before screening), those who have been diagnosed with solid cancer and are currently undergoing chemotherapy or those whose hepatocellular carcinoma has been confirmed by screening tests 2. Patients who underwent portal systemic shunting in the jugular vein 3. Patients with alcohol consumption or hepatotoxic drugs within 6 months prior to screening 4. Persons taking high-dose steroids, immunosuppressants, or antimicrobials due to severe infections for at least 1 month of screening 5. Those who have major surgical operations, long-term biopsy, or significant trauma as judged by the investigator within 3 months before screening 6. Those whose history of gastrointestinal bleeding is confirmed within 10 days of screening 7. Those whose medical history or accompanying diseases following the screening time is confirmed * If you have not been diagnosed with a malignant blood disease (acute myelogenous leukemia, acute lymphocytic leukemia, non-Hodgkins lymphoma, Hodgkins lymphoma, multiple myelopathy) * Severe aplastic anemia * Liver transplant history * Liver diseases of other causes besides alcoholic cirrhosis: hepatitis B and C, autoimmune liver disease (primary cholangitis, primary sclerosing cholangitis and autoimmune hepatitis, etc.), weak liver toxicity, non-alcoholic fatty liver disease , NAFLD), Wilson's disease, iron excess, alpha-1-antitrypsin deficiency, etc.) * Extrahepatic biliary stenosis * Active portal vein or hepatic vein thrombosis * Heart failure or respiratory failure * Severe renal impairment (when the result of serum creatinine test exceeds 1.5 times the upper limit of normal) * Acute or chronic infection requiring systemic treatment * Severe coagulation disorder (if the tester judges it as a severe coagulation disorder or one of the following 1 to 3; 1. bleeding predisposition, 2. coagulation, 3. platelet≤50,000/mm3 and INR≥1.5) 8. serologic test result (HIV, HAV, HBV, HCV, Syphilis infection) positive factor 9. Patients unable to collect bone marrow due to bone marrow disease 10. Those with a history of gentamicin hypersensitivity reaction 11. Pregnant or lactating women 12. Those with substance abuse experience within 1 year before screening 13. Those who participated in other clinical trials within one month before screening and administered (or applied) clinical trial drugs (or medical devices) 14. Those who previously participated in clinical trials related to cell therapy 15. Patients judged to be inappropriate to participate in this clinical trial due to complications, etc., when judged by the investigator before screening or registration

Locations (15)

Korea University Ansan Hospital

Ansan, South Korea

RECRUITING

Soonchunhyang University Hospital

Bucheon-si, South Korea

RECRUITING

Soonchunhyang University Hospital

Cheonan, South Korea

TERMINATED

Gangwon National University Hospital

Chuncheon, South Korea

TERMINATED

Hallym Univ. Medical Center

Chuncheon, South Korea

RECRUITING

Gangneung Asan Hospital

Gangneung-si, South Korea

RECRUITING

Eunpyeong St. Mary's Hospital

Seoul, South Korea

RECRUITING

Gangnam Severance Hospital

Seoul, South Korea

RECRUITING

Korea University Anam Hospital

Seoul, South Korea

RECRUITING

Seoul National University Hospital

Seoul, South Korea

RECRUITING

...and 5 more locations

Outcomes

Primary Outcomes

Transplant free survival (TFS)

Transplant free survival (TFS), the median survival time and 95% confidence interval for each group were presented using the Kaplan-Meier method, and the difference in the survival distribution between the two groups was used as a Cox proportional hazards model corrected for stratification Black.

Time frame: For 3 years

Secondary Outcomes

Survival rate

For the survival rate, the survival rate and 95% confidence interval at each time point are presented using the Kaplan-Meier method, and the difference in survival rate between the two groups is tested using the Z statistic.

Time frame: month 24 and 36

Change amount of Child-Pugh score

In order to compare the difference between groups in the amount of change in each evaluation variable at the time of visit after cell administration/best supportive therapy compared to the baseline value, covariance analysis (ANCOVA) is performed by setting the baseline time point and stratification factor as a correction variable for each evaluation variable. CP score was calculated using five factors: hepatic encephalopathy, prothrombin time, bilirubin, serum albumin, and ascites, and the score range was 5-15 points. In the Child-Pugh grade, scores of the five factors are summed and evaluated as A if it is less than 7 points, B if it is 7-9, and C if it exceeds 9 points.

Time frame: week -6 and 0

Change amount of MELD score

Time frame: week -6 and 0

Change amount of Liver function test

Time frame: month 0, 1, 3, 6, 9, 12, 18 and 24

Change amount of Fibrosis-4

Time frame: month 0, 6, 12, 18 and 24

Change amount of FibroScanⓇ

Time frame: week -6 and 0

Change amount of EQ-5D

Time frame: month -1, 6, 12, 18 and 24

Change amount of EQ-VAS

Time frame: month -1, 6, 12, 18 and 24

Clinical Trial to Evaluate the Efficacy and Safety of Cellgram-LC Administration in Patients With Alcoholic Cirrhosis

Overview

Conditions

Interventions

Eligibility

Locations (15)

Outcomes

Primary Outcomes

Secondary Outcomes

Central Contacts